1/1
Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to <24 Months with Mild‑to‑Moderate Atopic Dermatitis: A Phase IV Open‑Label Study (CrisADe CARE 1)
Version 2 2021-09-15, 20:53
Version 1 2021-09-15, 08:45
media
posted on 2021-09-15, 20:53 authored by Adis Journals on behalf of:, Joel Schlessinger, Julie S. Shepard, Richard Gower, John C. Su, Charles Lynde, Amy Cha, William C. Ports, Vivek Purohit, Liza Takiya, John L. Werth, Chuanbo Zang, Bonnie Vlahos, on behalf of the CARE 1 InvestigatorsThe above video abstract and plain language summary represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2020
